Jazz Pharmaceuticals has initiated patient dosing in a clinical trial intravenously (IV) administering Erwinaze in acute lymphoblastic leukemia (ALL) patients hypersensitive to asparaginase therapy derived from E. coli. The trial will ...
Tags: pharmeceuticals, clinical, trial intravenously, E.coli